ADAMTS18 and lung carcinoma: Furthermore, the mechanism by which ADAMTS18 increases the sensitivity of lung cancer cells to cisplatin is that ADAMTS18 acts as an inhibitor of epidermal growth factor receptor/protein kinase B (EGFR/AKT) signaling antagonist (28).